Manuscripts and Publications

Filters: Author is Harris, D Robert  [Clear All Filters]
Publication
Straub DM, Arrington-Sanders R, D Harris R, Willard N, Kapogiannis B, Emmanuel P, Futterman D, Ellen JM.  2011.  Correlates of HIV testing history among urban youth recruited through venue-based testing in 15 US cities.. Sex Transm Dis. 38(8):691-6.
Rubinstein ML, D Harris R, Rudy BJ, Kapogiannis BG, Aldrovandi GM, Mulligan K.  2014.  Exploration of the Effect of Tobacco Smoking on Metabolic Measures in Young People Living with HIV.. AIDS Res Treat. 2014:740545.
Barnes W, D'Angelo L, Yamazaki M, Belzer M, Schroeder S, Palmer-Castor J, Futterman D, Kapogiannis B, Muenz L, D Harris R et al..  2010.  Identification of HIV-infected 12- to 24-year-old men and women in 15 US cities through venue-based testing.. Arch Pediatr Adolesc Med. 164(3):273-6.
Naar-King S, Parsons JT, Murphy DA, Chen X, D Harris R, Belzer ME.  2009.  Improving health outcomes for youth living with the human immunodeficiency virus: a multisite randomized trial of a motivational intervention targeting multiple risk behaviors.. Arch Pediatr Adolesc Med. 163(12):1092-8.
Mulligan K, D Harris R, Emmanuel P, Fielding RA, Worrell C, Kapogiannis BG, Monte D, Sleasman J, Wilson CM, Aldrovandi GM.  2012.  Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B.. Clin Infect Dis. 55(3):461-8.
Naar-King S, Parsons JT, Murphy D, Kolmodin K, D Harris R.  2010.  A multisite randomized trial of a motivational intervention targeting multiple risks in youth living with HIV: initial effects on motivation, self-efficacy, and depression.. J Adolesc Health. 46(5):422-8.
Mulligan K, D Harris R, Monte D, Stoszek S, Emmanuel P, Hardin DS, Kapogiannis BG, Worrell C, Meyer WA, Sleasman J et al..  2010.  Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021.. Clin Infect Dis. 50(1):106-14.
Rudy BJ, Murphy DA, D Harris R, Muenz L, Ellen J.  2009.  Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions.. AIDS Patient Care STDS. 23(3):185-94.
Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR et al..  2008.  Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.. Antimicrob Agents Chemother. 52(2):631-7.
Rudy BJ, Murphy DA, D Harris R, Muenz L, Ellen J.  2010.  Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States.. AIDS Patient Care STDS. 24(2):97-104.
Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, Liu N, D Harris R, Mulligan K, Zimet G et al..  2017.  Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.. JAMA Pediatr. 171(11):1063-1071.
Wilson EC, Garofalo R, D Harris R, Belzer M.  2010.  Sexual risk taking among transgender male-to-female youths with different partner types.. Am J Public Health. 100(8):1500-5.
Lee S, Yamazaki M, D Harris R, Harper GW, Ellen J.  2015.  Social Support and Human Immunodeficiency Virus-Status Disclosure to Friends and Family: Implications for Human Immunodeficiency Virus-Positive Youth.. J Adolesc Health. 57(1):73-80.
Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, D Harris R et al..  2018.  Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.. Clin Infect Dis. 66(2):220-228.
Jennings JM, Ellen JM, Deeds BGriffin, D Harris R, Muenz LR, Barnes W, Lee SS, Auerswald CL.  2009.  Youth living with HIV and partner-specific risk for the secondary transmission of HIV.. Sex Transm Dis. 36(7):439-44.